Federal contractor · PARIS 8

OSIVAX

No contract obligations recorded for OSIVAX in FY2026. Since FY2025: $20.2M. Its largest customer was Office of Assistant Secretary for Preparedness and Response ($0).

Obligations · FY2026
$0
New awards
2
Sole-source
—
Single offer
—
UEI
M4YDKJJRJYC7
Other than small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 20.2MFY2025
  2. 0FY2026

Top buying agencies

Obligations in FY2026.

  1. Office of Assistant Secretary for Preparedness and Response$00.0%
    2 awards

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Largest awards

  1. OSIVAX - CLINICAL PROOF OF CONCEPT OF OVX836, A SINGLE-SHOT BROADLY PROTECTIVE INFLUENZA A VACCINE FOR IMMEDIATE PROTECTION AGAINST EMERGING PANDEMIC STRAINS$19.5M
    Office of Assistant Secretary for Preparedness and Response· Research & development· Jul 25, 2025 – May 19, 2026· 75A50125C00008
  2. OXIVAX - AOI #28: INFLUENZA VACCINE INNOVATION. ADVANCING METAGENOMIC NEXT-GENERATION SEQUENCING BASED AGNOSTIC DIAGNOSTICS FOR VIRAL PATHOGENS THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO PREPARE THE IND PACKAGE FOR OVX836+SQ ADJUVANT.$744K
    Office of Assistant Secretary for Preparedness and Response· Research & development· Sep 19, 2025 – Feb 2, 2026· 75A50125C00006

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

OSIVAX received $0 in federal assistance in FY2026, on 1 actions (0 new awards), −100% vs FY2025.

Assistance · FY2026
$0
New awards
0
Actions
1
Since FY2023
$1.5M

Assistance by fiscal year

  1. 529.9KFY2023
  2. 526.3KFY2024
  3. 484.1KFY2025
  4. 0FY2026

Largest awards

  1. BROAD SPECTRUM PROTECTION AND IMMUNE RESPONSES INDUCED BY AN NP-BASED UNIVERSAL INFLUENZA VACCINE IN HETEROLOGOUS NHP CHALLENGE MODEL…$1.5M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Sep 26, 2023 – Jul 30, 2026· R01AI177376

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 6, 2026, loaded Oct 6, 2026 · FY2023–FY2026.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 1 market (agency × industry), FY2024–FY2026.

  1. GIGAGEN INC$19.6M
    SAN CARLOS, CA · 97% of this company's obligations are in markets they both serveOffice of Assistant Secretary for Preparedness and Response · Scientific research and development services
  2. PRENOSIS, INC$21.5M−100% in FY2026
    CHICAGO, IL · 99% of this company's obligations are in markets they both serveOffice of Assistant Secretary for Preparedness and Response · Scientific research and development services
  3. SCYNEXIS INC$18.5M
    JERSEY CITY, NJ · 91% of this company's obligations are in markets they both serveOffice of Assistant Secretary for Preparedness and Response · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 6, 2026, loaded Oct 6, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 6, 2026, loaded Oct 6, 2026.